AI assistant
10x Genomics, Inc. — Director's Dealing 2019
Sep 16, 2019
31830_dirs_2019-09-16_ab250979-f740-4044-8557-052cfebafa8b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2019-09-16
Reporting Person: SULIMAN SHEHNAAZ (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-09-16 | Stock Option (right to buy) | $30.00 | J | 100000 | Disposed | 2029-08-07 | Class B Common Stock (100000) | Direct |
| 2019-09-16 | Stock Option (right to buy) | $30.00 | J | 100000 | Acquired | 2029-08-07 | Class A Common Stock (100000) | Direct |
Footnotes
F1: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering.
F2: One forty-eighth of the shares subject to the option vested on September 7, 2019, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. This option may be exercised prior to vesting, subject to the Issuer's right to repurchase unvested shares.